News about Gilead Sciences
The blockbuster public offering pegs Allogene's market value at more than $2 billion.
Celgene and Novartis are among the companies accused of thwarting generic drugs.
On hot technologies like CRISPR and CAR-T, China has a leg up, Goldman says.
The new cure could be a boon to poorer nations.
The PrEP drug will be publicly funded in New Zealand for those at high risk for HIV infection.